D. E. Shaw & Co., Inc. Avadel Pharmaceuticals PLC Transaction History

D. E. Shaw & Co., Inc.

$107 Billion
Q3 2024

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$12.55 - $17.22 $1.44 Million - $1.97 Million	-114,445 Reduced 58.23%	82,109 $1.39 Million
Q4 2023 Feb 14, 2024	SELL	$9.64 - $14.59 $3.4 Million - $5.15 Million	-352,816 Reduced 64.22%	196,554 $2.78 Million
Q3 2023 Nov 14, 2023	SELL	$10.3 - $15.99 $2.23 Million - $3.46 Million	-216,466 Reduced 28.27%	549,370 $5.66 Million
Q2 2023 Aug 14, 2023	BUY	$8.48 - $16.48 $3.85 Million - $7.49 Million	454,546 Added 146.02%	765,836 $12.6 Million
Q1 2023 May 15, 2023	SELL	$6.41 - $9.95 $208,100 - $323,026	-32,465 Reduced 9.44%	311,290 $2.85 Million
Q4 2022 Feb 14, 2023	SELL	$5.02 - $10.0 $41,962 - $83,590	-8,359 Reduced 2.37%	343,755 $2.46 Million
Q3 2022 Nov 14, 2022	BUY	$2.57 - $7.31 $870,412 - $2.48 Million	338,682 Added 2521.46%	352,114 $1.76 Million
Q2 2022 Aug 15, 2022	BUY	$1.07 - $6.95 $14,372 - $93,352	13,432 New	13,432 $33,000
Q4 2021 Feb 14, 2022	SELL	$7.34 - $11.18 $242,520 - $369,398	-33,041 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$6.49 - $9.91 $125,938 - $192,303	19,405 Added 142.31%	33,041 $324,000
Q2 2021 Aug 16, 2021	BUY	$6.73 - $9.05 $91,770 - $123,405	13,636 New	13,636 $92,000
Q4 2020 Feb 16, 2021	SELL	$5.03 - $7.95 $102,320 - $161,718	-20,342 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$5.02 - $8.98 $381,881 - $683,126	-76,072 Reduced 78.9%	20,342 $103,000
Q2 2020 Aug 14, 2020	BUY	$7.25 - $11.75 $699,001 - $1.13 Million	96,414 New	96,414 $779,000
Q1 2020 May 15, 2020	SELL	$4.06 - $10.64 $57,319 - $150,215	-14,118 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$3.34 - $7.7 $47,154 - $108,708	14,118 New	14,118 $107,000
Q3 2019 Nov 14, 2019	SELL	$1.92 - $4.47 $33,456 - $77,889	-17,425 Closed	0 $0
Q2 2019 Aug 14, 2019	SELL	$1.09 - $3.19 $17,952 - $52,539	-16,470 Reduced 48.59%	17,425 $50,000
Q1 2019 May 15, 2019	SELL	$1.44 - $3.29 $17,206 - $39,312	-11,949 Reduced 26.06%	33,895 $49,000
Q4 2018 Feb 14, 2019	SELL	$1.74 - $4.66 $37,751 - $101,103	-21,696 Reduced 32.12%	45,844 $118,000
Q3 2018 Nov 14, 2018	SELL	$4.08 - $7.14 $432,973 - $757,703	-106,121 Reduced 61.11%	67,540 $297,000
Q2 2018 Aug 14, 2018	BUY	$5.89 - $7.78 $460,592 - $608,388	78,199 Added 81.92%	173,661 $1.07 Million
Q1 2018 May 15, 2018	SELL	$6.76 - $11.7 $1.09 Million - $1.89 Million	-161,517 Reduced 62.85%	95,462 $696,000
Q4 2017 Feb 14, 2018	BUY	$8.03 - $11.25 $22,363 - $31,331	2,785 Added 1.1%	256,979 $2.11 Million
Q3 2017 Nov 14, 2017	BUY	$8.35 - $10.5 $2.12 Million - $2.67 Million	254,194	254,194 $2.67 Million

Others Institutions Holding AVDL

# of Institutions

Shares Held

1.07M

Call Options Held

Put Options Held

View Full List

About AVADEL PHARMACEUTICALS PLC

Ticker AVDL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 60,581,300
Market Cap $650M
Description
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and...

More about AVDL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account